

NEW: Verzenio is now approved for patients with HR+, HER2-, node positive Early Breast Cancer at high-risk of recurrence.




Although the prognosis for HR+, HER2- early breast cancer (EBC) is generally positive¹

20-30% of patients could progress to incurable metastatic disease¹



Factors associated with high risk of recurrence can include²:



Positive nodal status



High tumour grade



Large tumour size




Consider Verzenio for a significant improvement in invasive disease-free survival for your patients³



References: 1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet*. 2005;365(9472):1687-1717. doi:10.1016/S0140-6736(05)66544-0. 2. Cheng L, Swartz MD, Zhao H, et al. Hazard of recurrence among women after primary breast cancer treatment—a 10-year follow-up using data from SEER-Medicare. *Cancer Epidemiol Biomarkers Prev*. 2012;21(5):800-809. 3. N.Harbeck, P.Rastogi, et al. (2021). Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Published by Elsevier on behalf of European Society for Medical Oncology.

See the effects of potent, continuous cell cycle arrest with Verzenio^{1,2}

Verzenio provides targeted inhibition of CDK4 & 6³



Continuous exposure to Verzenio (in vitro):³

- Inhibited Rb phosphorylation
- Blocked cell-cycle progression from G1 into S phase
- Resulted in senescence and apoptosis

Enzymatic studies of CDK4 and CDK6 were completed with binding partners Cyclin D1 and Cyclin D3, respectively. Verzenio inhibits both CDK4 and CDK6.²⁻⁴


Inhibiting CDK4 & 6 in healthy cells can result in side effects, some of which may be serious.

Rb=retinoblastoma.

Verzenio is 14x more selective for CDK4 than CDK6 in enzymatic assays^{1,2}

monarchE enrolled 5,637 node-positive patients (ITT population) with a range of familiar high-risk disease characteristics^{1,2}

Global, phase III, open-label randomised, 2-cohort study



This schematic shows the monarchE ITT study population, which comprises monarchE cohorts 1 and 2. The abemaciclib adjuvant indication was supported by results in patients in Cohort 1 only.
ALN, axillary lymph nodes; **ITT**, intention-to-treat; **IDFS**, invasive disease-free survival; **DRFS**, distant relapse-free survival; **OS**, overall survival.

The benefit of Abemaciclib arm is sustained beyond the 2-year treatment period.⁴





Verzenio: The only CDK4 & 6 inhibitor that can be taken every day without a planned break (continuous dosing)¹⁻³

150 mg

2 x Daily

The recommended dose of Verzenio is 150 mg twice daily when used in combination with ET¹



References: 1. VERZENIO [Package Insert dated 10 August 2022] Singapore. Eli Lilly (Singapore) Pte Ltd, 2022. Accessed on 10 August 2022. 2. Pfizer Ibrance EPAR July 2021 3. Kisqali EPAR. November 2020



Before prescribing Verzenio (abemaciclib), please consult the full local prescribing information by scanning the following QR code.

SAFETY REPORTING FOR POTENTIAL UNDESIRABLE EFFECTS:
Please report adverse events to the DKSH Singapore Pte Ltd at HEC-RA.Sin@dksh.com

Market Expansion
Services by
www.dksh.com



DKSH Singapore Pte Ltd
47 Jalan Buroh, #09-01, Singapore 619491
Phone +65 6471 1466